PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 11, 2012--
Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that it has
commenced an underwritten public offering of shares of its common stock.
All of the shares in the offering are to be sold by Pacira.
Jefferies & Company, Inc. and Barclays Capital Inc. are acting as joint
book-running managers for the offering. Piper Jaffray & Co., Wedbush
PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as
co-managers for the offering. Pacira intends to grant the underwriters a
30-day option to purchase up to an additional 15 percent of the shares
of common stock sold in the offering to cover over-allotments, if any.
The offering is subject to market and other conditions, and there can be
no assurance as to whether or when the offering may be completed, or as
to the actual size or terms of the offering.
A shelf registration statement on Form S-3 relating to the public
offering of the shares of common stock described above was filed with
the Securities and Exchange Commission (SEC) and is effective. A
preliminary prospectus supplement relating to the offering has been
filed with the SEC and is available on the SEC’s website located at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus may be obtained from Jefferies & Company, Inc., Attention:
Equity Syndicate Prospectus Department, at 520 Madison Avenue, 12th
Floor, New York, NY 10022, or by telephone at 877-547-6340 or by email
or from Barclays Capital Inc., c/o Broadridge Financial
Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling
1-888-603-5847 or by emailing Barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) is an emerging specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable suspension),
was approved for administration into the surgical site to produce
postsurgical analgesia by the U.S. Food and Drug Administration in
October 2011. EXPAREL and two other commercially available products
utilize the Pacira proprietary product delivery technology DepoFoam®, a
unique platform that encapsulates drugs without altering their molecular
structure and then releases them over a desired period of time.
Additional information about Pacira is available at www.pacira.com.
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to our expectations
regarding the completion of the proposed public offering. Actual results
or developments may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties related
to whether or not we will be able to raise capital through the sale of
shares of common stock, the final terms of the proposed offering, market
and other conditions, the satisfaction of customary closing conditions
related to the proposed public offering and the impact of general
economic, industry or political conditions in the United States or
internationally. There can be no assurance that we will be able to
complete the proposed public offering on the anticipated terms, or at
all. Additional risks and uncertainties relating to the proposed
offering, Pacira and our business are discussed in the "Risk Factors"
section of our most recent Annual Report on Form 10-K for the fiscal
year ended December 31, 2011, in other filings that we periodically make
with the SEC and in the preliminary prospectus supplement related to the
proposed offering filed with the SEC on or about the date hereof. In
addition, the forward-looking statements included in this press release
represent our views as of the date of this press release. We anticipate
that subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
at some point in the future, we specifically disclaim any obligation to
do so. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570